Auris Medical (EARS) to Release Quarterly Earnings on Thursday

Share on StockTwits

Auris Medical (NASDAQ:EARS) will announce its earnings results before the market opens on Thursday, November 15th.

Auris Medical (NASDAQ:EARS) last posted its quarterly earnings results on Wednesday, August 15th. The biotechnology company reported ($0.51) earnings per share (EPS) for the quarter. On average, analysts expect Auris Medical to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

EARS stock traded down $0.04 during trading on Friday, reaching $0.68. 4,111 shares of the stock traded hands, compared to its average volume of 14,465,029. Auris Medical has a 52-week low of $0.23 and a 52-week high of $9.50. The company has a market cap of $4.69 million, a PE ratio of -0.12 and a beta of -1.09.

A number of equities research analysts have issued reports on EARS shares. Eurobank EFG started coverage on Auris Medical in a research report on Monday, October 8th. They set a “buy” rating and a $2.50 price target for the company. ValuEngine raised Auris Medical from a “hold” rating to a “buy” rating in a research report on Thursday, November 1st.

COPYRIGHT VIOLATION NOTICE: “Auris Medical (EARS) to Release Quarterly Earnings on Thursday” was posted by Macon Daily and is the property of of Macon Daily. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The original version of this news story can be accessed at https://macondaily.com/2018/11/09/auris-medical-ears-to-release-quarterly-earnings-on-thursday.html.

About Auris Medical

Auris Medical Holding AG, a clinical-stage biopharmaceutical company, focuses on the development of novel products for the treatment of inner ear disorders. Its product candidates include AM-101, which is in phase III clinical development for the treatment of acute inner ear tinnitus; and AM-111 that is in phase III clinical development for the treatment of acute inner ear hearing loss.

Read More: Moving Average (MA)

Earnings History for Auris Medical (NASDAQ:EARS)

Receive News & Ratings for Auris Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auris Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply